Human Reproduction, Vol. 14, No. 3, 683-688,
March 1999
© 1999 European Society of Human Reproduction and Embryology
Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation
1 Departments of Obstetrics and Gynecology, 2 Biochemistry and 3 Reproductive Biology, A. Béclère Hospital, 157, Rue de la Porte de Trivaux, 92140 Clamart Cedex, France and 4 Department of Endocrinology, St Antoine Hospital, 184, Fbg Saint Antoine, 75012 Paris, France
Natural cycles were abandoned in in-vitro fertilization (IVF) embryo transfer, due to premature luteinizing hormone (LH) surges–and subsequent high cancellation rates. In this study, we investigated the administration of a new gonadotrophin-releasing hormone antagonist (Cetrorelix) in the late follicular phase of natural cycles in patients undergoing IVF and intracytoplasmic sperm injection (ICSI). A total of 44 cycles from 33 healthy women [mean age 34.1 ± 1.4 (range 26–36) years] were monitored, starting on day 8 by daily ultrasound and measurement of serum concentrations of oestradiol, LH, follicle stimulating hormone (FSH) and progesterone. When plasma oestradiol concentrations reached 100–150 pg/ml, with a lead follicle between 12–14 mm diameter, a single injection (s.c.) of 0.5 mg (19 cycles) or 1 mg (25 cycles) Cetrorelix was administered. Human menopausal gonadotrophin (HMG; 150 IU) was administered daily at the time of the first injection of Cetrorelix, and repeated thereafter until human chorionic gonadotrophin (HCG) administration. Four out of 44 cycles were cancelled (9.0%). No decline in follicular growth or oestradiol secretion was observed after Cetrorelix administration. A total of 40 oocyte retrievals leading to 22 transfers (55%) was performed. In 10 cycles (25%), no oocyte was obtained. Fertilization failure despite ICSI occurred in six cycles (15%). In two patients the embryo was arrested at the 2 pronuclear (PN) stage. The stimulation was minimal (4.7 ± 1.4 HMG ampoules). A total of seven clinical pregnancies was obtained (32.0% per transfer, 17.5% per retrieval), of which five are ongoing. Thus, a spontaneous cycle and the GnRH antagonist Cetrorelix in single dose administration could represent a first-choice IVF treatment with none of the complications and risks of current controlled ovarian hyperstimulation protocols, and an acceptable success rate.
Key words: gonadotrophin-releasing hormone antagonist/in-vitro fertilization–embryo transfer/spontaneous cycle
5 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K.J. Middelburg, M.J. Heineman, A.F. Bos, M. Pereboom, V. Fidler, and M. Hadders-Algra The Groningen ART cohort study: ovarian hyperstimulation and the in vitro procedure do not affect neurological outcome in infancy Hum. Reprod., September 12, 2009; (2009) dep310v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Pelinck, H.M. Knol, N.E.A. Vogel, E.G.J.M. Arts, A.H.M. Simons, M.J. Heineman, and A. Hoek Cumulative pregnancy rates after sequential treatment with modified natural cycle IVF followed by IVF with controlled ovarian stimulation Hum. Reprod., August 1, 2008; 23(8): 1808 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frydman and C. Ranoux INVO: a simple, low cost effective assisted reproductive technology ESHRE Monogr, July 1, 2008; 2008(1): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nargund, B.C.J.M. Fauser, N.S. Macklon, W. Ombelet, K. Nygren, R. Frydman, and for the Rotterdam ISMAAR Consensus Group on Termin The ISMAAR proposal on terminology for ovarian stimulation for IVF Hum. Reprod., November 1, 2007; 22(11): 2801 - 2804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Pelinck, N.E.A. Vogel, E.G.J.M. Arts, A.H.M. Simons, M.J. Heineman, and A. Hoek Cumulative pregnancy rates after a maximum of nine cycles of modified natural cycle IVF and analysis of patient drop-out: a cohort study Hum. Reprod., September 1, 2007; 22(9): 2463 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Pelinck, N.E.A. Vogel, A. Hoek, A.H.M. Simons, E.G.J.M. Arts, M.H. Mochtar, S. Beemsterboer, M.N. Hondelink, and M.J. Heineman Cumulative pregnancy rates after three cycles of minimal stimulation IVF and results according to subfertility diagnosis: a multicentre cohort study Hum. Reprod., September 1, 2006; 21(9): 2375 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen GnRH antagonists in ovarian stimulation for IVF Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Pelinck, N.E.A. Vogel, A. Hoek, E.G.J.M. Arts, A.H.M. Simons, and M.J. Heineman Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study Hum. Reprod., March 1, 2005; 20(3): 642 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Kolibianakis, K. Zikopoulos, M. Camus, H. Tournaye, A. Van Steirteghem, and P. Devroey Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation Hum. Reprod., November 1, 2004; 19(11): 2545 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Young, C. L. Chaffin, T. A. Molskness, and R. L. Stouffer Controlled ovulation of the dominant follicle: a critical role for LH in the late follicular phase of the menstrual cycle Hum. Reprod., November 1, 2003; 18(11): 2257 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.K. Omland, P. Fedorcsak, R. Storeng, P.O. Dale, T. Abyholm, and T. Tanbo Different aetiological mechanisms for unexplained and endometriosis-associated infertility cannot be inferred from unstimulated IVF cycles using HCG to induce ovulation Hum. Reprod., July 1, 2002; 17(7): 1927 - 1927. [Full Text]
|
|
|
|
|
|
H. Al-Inany and M. Aboulghar GnRH antagonist in assisted reproduction: a Cochrane review Hum. Reprod., April 1, 2002; 17(4): 874 - 885. [Abstract] [Full Text]
|
|
|
|
|
|
A.K. Omland, P. Fedorcsak, R. Storeng, P.O. Dale, T. Abyholm, and T. Tanbo Natural cycle IVF in unexplained, endometriosis-associated and tubal factor infertility Hum. Reprod., December 1, 2001; 16(12): 2587 - 2592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.R. Hernandez Avoiding multiple pregnancies: sailing uncharted seas Hum. Reprod., April 1, 2001; 16(4): 615 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Ingerslev, A. Hojgaard, J. Hindkjar, and U. Kesmodel A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate Hum. Reprod., April 1, 2001; 16(4): 696 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Albano, R.E. Felberbaum, J. Smitz, H. Riethmuller-Winzen, J. Engel, K. Diedrich, and P. Devroey Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin Hum. Reprod., March 1, 2000; 15(3): 526 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Out, D. D.M. Braat, B. M.E. Lintsen, T. Gurgan, O. Bukulmez, O. Gokmen, G. Keles, P. Caballero, J. M. Gonzalez, F. Fabregues, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon(R)) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation Hum. Reprod., January 1, 2000; 15(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.M.J. Janssens, C.B. Lambalk, R. Schats, and J. Schoemaker Successful in-vitro fertilization in a natural cycle after four previously failed attempts in stimulated cycles: Case report Hum. Reprod., October 1, 1999; 14(10): 2497 - 2498. [Abstract] [Full Text] [PDF]
|
|